{"id":"amlodipine-camsylate","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Peripheral edema"},{"rate":"5-10%","effect":"Headache"},{"rate":"2-5%","effect":"Flushing"},{"rate":"2-5%","effect":"Fatigue"},{"rate":"1-3%","effect":"Dizziness"},{"rate":"1-3%","effect":"Palpitations"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a dihydropyridine calcium channel blocker, amlodipine camsylate selectively inhibits the inward movement of calcium ions through L-type calcium channels in the cell membrane of vascular smooth muscle cells. This reduces intracellular calcium concentration, preventing smooth muscle contraction and leading to vasodilation of coronary and peripheral arteries. The camsylate salt form is a specific formulation variant of amlodipine designed to improve solubility and bioavailability.","oneSentence":"Amlodipine camsylate blocks L-type calcium channels in vascular smooth muscle and cardiac tissue, reducing calcium influx and causing vasodilation and decreased blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:21:43.889Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Angina pectoris (chronic stable angina and vasospastic angina)"}]},"trialDetails":[{"nctId":"NCT01277822","phase":"PHASE4","title":"Efficacy of Losartan + Amlodipine Compared to Amlodipine Alone in the Treatment of Uncontrolled High Blood Pressure (MK-0954F-399)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-05-30","conditions":"Hypertension","enrollment":334},{"nctId":"NCT05462535","phase":"","title":"An Observational Study to Evaluate Effectiveness and Safety of Amosartan Plus Tablet","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2018-02-26","conditions":"Hypertension,Essential","enrollment":4785},{"nctId":"NCT01830517","phase":"PHASE4","title":"Diurnal Variation in Hypertensive Stroke Patients","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2007-08","conditions":"Hypertension, Stroke","enrollment":84},{"nctId":"NCT01127217","phase":"PHASE3","title":"Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Stage 2 Hypertension","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2009-05","conditions":"Hypertension","enrollment":149}],"_emaApprovals":[],"_faersSignals":[{"count":6,"reaction":"OFF LABEL USE"},{"count":5,"reaction":"FALL"},{"count":5,"reaction":"MULTIPLE DRUG THERAPY"},{"count":3,"reaction":"ABDOMINAL PAIN"},{"count":3,"reaction":"ACUTE KIDNEY INJURY"},{"count":3,"reaction":"HAEMATOCHEZIA"},{"count":3,"reaction":"PYREXIA"},{"count":2,"reaction":"CLOSTRIDIUM DIFFICILE INFECTION"},{"count":2,"reaction":"DECREASED APPETITE"},{"count":2,"reaction":"DUODENAL ULCER"}],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Amlodipine camsylate","genericName":"Amlodipine camsylate","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amlodipine camsylate blocks L-type calcium channels in vascular smooth muscle and cardiac tissue, reducing calcium influx and causing vasodilation and decreased blood pressure. Used for Hypertension, Angina pectoris (chronic stable angina and vasospastic angina).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}